Christopher Campbell, MD
Urology · Rogers, ARNPI 1689037186
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (47.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 29 manufacturers reported payments, led by Intuitive Surgical at 47.0% of the total. Reporting peaked in 2022 at $7,660 and has fallen 84.5% since, to $1,188 in 2025.
Across 157 payments — averaging $81.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- Boston Scientific$2K
- Procept Biorobotics Corporation$2K
- Axonics, Inc.$641
- Medtronic$548
- Agiliti Health, Inc.$300
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$4083%
- Travel & lodging$1,49512%
- Food & beverage$4,85238%
- Education$6,00047%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 2 | $6,000 |
| Boston Scientific | 27 | $2,186 |
| Procept Biorobotics Corporation | 12 | $1,584 |
| Axonics, Inc. | 12 | $641 |
| Medtronic | 25 | $548 |
| Agiliti Health, Inc. | 7 | $300 |
| Coloplast | 17 | $295 |
| Endo Pharmaceuticals Inc. | 4 | $172 |
| Teleflex LLC | 4 | $137 |
| AbbVie | 7 | $123 |
| Urogen Pharma, Inc. | 4 | $85 |
| Myovant Sciences Inc. | 5 | $85 |
| Pfizer | 4 | $79 |
| Astellas Pharma US Inc | 2 | $63 |
| Bayer | 3 | $62 |
| Merck | 3 | $61 |
| Novo Nordisk | 3 | $51 |
| Olympus America Inc. | 2 | $38 |
| Blue Earth Diagnostics | 2 | $36 |
| Tolmar Pharmaceuticals, Inc. | 2 | $35 |
| Myriad Genetic Laboratories, Inc. | 2 | $33 |
| 180 Medical, Inc. | 1 | $26 |
| Kowa Pharmaceuticals America, Inc. | 1 | $19 |
| Ambu Inc. | 1 | $17 |
| Alfasigma USA, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Johnson & Johnson | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Recordati_rare_diseases_inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DAVINCI XI$6,000
- AquaBeam Robotic System$1,273
- Axonics$514
- GENERAL ERECTILE DYSFUNCTION$337
- LithoVue$147
- XIAFLEX$125
- AMS 700$123
- INTERSTIM$116
- AQUABEAM SYSTEM$115
How this compares
$12,754 in reported general payments places this provider in the 65th percentile of 88 urology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 43 | $47,489 |
| MyrbetriqMirabegron | 24 | $23,361 |
| Trospium Chloride ErTrospium Chloride | 21 | $3,691 |
| Tamsulosin Hcl | 306 | $3,642 |
| Oxybutynin Chloride ErOxybutynin Chloride | 92 | $1,803 |
| Finasteride | 103 | $1,062 |
| NitrofurantoinNitrofurantoin Macrocrystal | 21 | $805 |
| Testosterone Cypionate | 12 | $489 |
| Cephalexin | 38 | $249 |
| Oxybutynin Chloride | 29 | $163 |
| Terazosin Hcl | 31 | $160 |
| Oxycodone Hcl | 45 | $109 |
| Ciprofloxacin Hcl | 20 | $105 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 27 | $99 |
| Levofloxacin | 14 | $70 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $16 | $47,48943 claims |
| Astellas Pharma US IncMyrbetriq | $63 | $23,36124 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 88 urology providers in Arkansas.
Other urology in Rogers
- Jeffrey AllistonRogers$17K
- Robert ZimmermanRogers$15K
- Matthew KincadeRogers$9K
- William BrockwayRogers$3K
- Orlando Aguilar-GuzmanRogers$3K
- Donald MooneyLittle Rock$148K
- Timothy GoodsonLittle Rock$147K
- Ronald KuhnNorth Little Rock$138K
- Caleb BozemanLittle Rock$136K
- David CoussensLittle Rock$134K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.